Nonetheless, little is known about the influence of tyrosine kinase inhibitors (TKIs) in immune responses derived from COVID-19 vaccines in NSCLC patients with EGFR and ALK alterations. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.